WebAug 5, 2024 · Exebacase . Exebacase is under investigation in clinical trial NCT03163446 (Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial … WebMar 2, 2024 · CF-301 (exebacase) is a recombinantly produced bacteriophage-derived lysin (cell wall hydrolase) and is the first agent of this class to enter clinical development in the United States for ...
Compassionate Use Case Study Demonstrating the Potential of ... - BioSpace
WebOct 4, 2024 · About Exebacase (CF-301): Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream... WebExebacase (CF-301) is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of a new treatment for … Our lead lysin, exebacase (CF-301) is an investigational product candidate that … Exebacase (CF-301) Exebacase is a novel, investigational lysin with potent activity … Exebacase (CF-301) Exebacase is a novel, investigational lysin with potent activity … Gary Woodnutt, Ph.D. Senior Vice President of Translational Sciences and … Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus … Roger J. Pomerantz, M.D., F.A.C.P. President, Chief Executive Officer and … About Contrafect Corporation. We are focused on developing first-in-class … Overview. Our therapeutic product candidates are direct lytic agents (DLAs) … Company Overview. ContraFect is a clinical-stage biotechnology company … Address: 28 Wells Avenue 3rd Floor Yonkers, NY 10701 US. Telephone: 914 … bd-re フォーマット ソフト
Contrafect And Its Narrowed Phase 3 Approach (NASDAQ:CFRX)
Web1 day ago · Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal ... WebSep 6, 2024 · "We are very pleased to have completed enrollment of this Phase 2 superiority study, which is a major milestone in the development of exebacase (CF-301) as a … WebFeb 17, 2024 · Exebacase (CF-301), a novel, anti-staphylococcal lysin (cell-wall hydrolase) is the first agent of this class to enter late-stage clinical development (Phase 3, NCT04160468) for the treatment of ... 印刷 製本 アクセア